🧠 Food for thought

Implications, context, and why it matters.

Vietnam’s biotech plan lacks detail on market pathways and regulatory benchmarks

• Vietnam has mastered CRISPR/Cas9 gene editing (a precise DNA-editing toolkit) and next-generation vaccines 1. The country supplies only 6% of drug raw materials, while local makers cover 10% of vaccination services beyond the national program 2.
• Only three pharmaceutical manufacturing projects qualify for investment incentives, while most fall short on scale 2. Only 17 factories meet European Union GMP (EU-GMP) or equivalent standards, and the strategy lists no specific regulatory reforms or Good Manufacturing Practice (GMP) facility targets 2.
• Approved research funding totals VND754 billion (~$29 million), which leaves an underinvestment gap officials have acknowledged 1.

Private operators can plug gaps with GMP facilities in hi-tech parks

• Private Contract Research Organization (CRO) operators can set up shared GMP labs plus pilot plants (small-scale production lines for process validation) within hi-tech parks (government-backed industrial zones with infrastructure for advanced manufacturing and research).
• Equipment leasing plus training for about 300 pharmaceutical factories 2 can speed commercialization. This helps firms work toward Pharmaceutical Inspection Co-operation Scheme GMP (PIC/S-GMP) standards (an international framework that harmonizes GMP inspections). That step supports access to export markets opened by Vietnam’s Free Trade Agreement (FTA) network, including the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) plus the EU-Vietnam Free Trade Agreement (EVFTA) 3.
• Biotech and pharma-focused investors can target industrial parks with ready space plus FDI incentives for entry before the 2026–2030 strategy rollout 4. Corporate income tax breaks, land rent reductions, import duty exemptions for eligible production and research and development (R&D) projects.